Da malo podignem ovu temu, a i da trudnice koje se pikaju heparinom i dijele iskustva na temi o heparinu ne opterecujem APSom i nekim ne-tako-ugodnim detaljima o njemu, kome zatreba, pronasla sam dobar pregled iz 2006 koji opisuje antifosfolipidni sindrom i terapiju heparinom+aspirinom, gdje lijepo objasnjavaju kako djelovanje heparina tu nije samo antikoagulacijski nego i protuupalno:

The antiphospholipid syndrome as a disorder initiated by inflammation: implications for the therapy of pregnant patients

http://www.nature.com/ncprheum/journ...prheum0432.pdf

Navode kako ispitivanje APSa na misevima ukazuje da su tu komplikacije u trudnoci izazvane upalnim stanjima a ne trombozom, te da su druge studije podcijenile vaznost tih upalnih mehanizama - umjesto da pokazuju vaskulopatije...aktivacije endotelijalnih stanica ... APS placente se razlikuju od kontrolnih po nakupinama upalnih stanica oko zila i po infiltraciji makrofaga... (kako sam "ponosni" vlasnik zbirke od 3 PHDa kiretmana na kojima nikada nisu zaboravili napisati nesto poput zarisno upalno infiltrirana, nekroticka decidua i sl... ovo mi je i osobno jako interesantno)

Sto se tice terapije kortikosteroidima i imuno globulinima - po njima to eventualno pomaze kad je uz APS prisutan aktivni SLE (sistematski lupus erimatozus), no ne cine mi se nesto odusevljenji s rezultatima takvih terapija:
Prednisone and other immunomodulating therapies are seldom prescribed for pregnant women with APS, but prednisone is appropriate for clinically active SLE, if present. A small study of APS patients with and without SLE who were treated with 40 mg prednisone daily or heparin (10,000 IU twice daily at 6–8 weeks, reduced to 2000 IU twice daily to attain normal activated partial thromboplastin time at mid trimester), both with concomitant low-dose aspirin (81 mg), demonstrated equally high rates of live births in both treatment groups. Yet, maternal complications were greater in the prednisone-treated group. Subsequent uncontrolled studies argued against the use of corticosteroid for pregnancies complicated by antiphospholipid antibodies, except if such treatment is needed for active SLE. For women who continue to abort spontaneously despite heparin treatment, anecdotal experience has suggested that intra venous immuno globulin is beneficial. A small, controlled trial of this treatment in unselected patients with antiphospholipid antibodies, however, showed no efficacy. The doses used ranged widely, from 0.4 g/kg body weight per trimester to 2.0 g/kg body weight monthly.